The outstanding issues the Company must deal with are as follows along with our action plan. (excerpt from Financial Results for FY 2016)
1. Expansion of development pipeline
The Company group aims at delivering our development pipelines to patients. The success probability of new drugs development decrease year by year, our development pipeline is at risk for delay, abeyance and abort of development by multiple matters. In order to deal with the risk, we think it necessary to expand the development pipeline. We will further promote discoveries of candidate compounds for new drugs through our fundamental research and proactively undertake in-licensing activities from universities and corporations to own multiple development pipeline comprised by various development stages.
2. Expansion of business field and promotion of licensing activities
The Company group aims at licensing out at relatively early stages, we consider that it is important for the improvement of our profitability, and we promote efforts of in-house development after a non-clinical study. In the future, we work on expanse of business field and make efforts for maximization of the profit.
Our important subject will be new collaborations with pharmaceutical companies because the Company’s profit is sourced from front money income through licensing out, milestone income and royalty income from launch. Therefore, we will improve the network with pharmaceutical companies and work on activities for achievement of licensing out as to partnerless development pipeline.
3. Development support of development pipelines already licensed out
Although the Company group reserves a launched drug present, in order to accomplish the sustainable corporate growth, the Company plans to undertake research and development activities, and expects the cost required for these activities to continue incurring.
For this reason, we will strive to build stable management infrastructure by supporting smooth clinical trials for the development products already licensed out to pharmaceutical companies in collaboration with them so as to achieve early launch of these development products.
4. Making the research and development system more efficient
The Company group is a bio-venture company have the substantial advantage of being able to create effective drug candidate compounds.
We will work on development of new drug candidates after a non-clinical study in a group, promote the use of external organizations such as universities and corporations and strive to an efficient research and development system.
5. Improving the financial ground
Aiming at generating an earnings structure of high value, the Company group plans expansion of pipeline and advancing stages of development. For this purpose we will improve our financial ground by fund raising from financial and capital markets as necessary.